Kestra Medical officer proposes $301K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kestra Medical Technologies, Ltd. (KMTS) is the issuer in a notice covering officer and director Brian Daniel Webster’s proposed sale of 15,000 common shares, with an aggregate market value of $300,671.04 and an approximate sale date of April 15, 2026. The shares were issued to him as restricted shares under the issuer’s equity compensation plan on January 21, 2026. The notice lists a Rule 10b5-1 plan adoption date of September 29, 2025. It also reports three prior sales by Brian Webster: 15,000 common shares on January 15, 2026, for gross proceeds of $342,023.69; 15,000 on February 17, 2026, for $384,020.06; and 15,000 on March 17, 2026, for $304,123.49.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Aggregate market value financial
Gross proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What recent sales does Brian Webster report for KMTS?
AI-generated analysis. How Rhea-AI works. Not financial advice.